title: Targeting the Mammalian Target of Rapamycin in Lung Cancer.
abstract: Lung cancer is the leading cause of cancer death worldwide. Despite advances in its prevention and management, the prognosis of patients with lung cancer remains poor. Therefore, much attention is being given to factors that contribute to the development of this disease, the mechanisms that drive oncogenesis and tumor progression and the search for novel targets that could lead to the development of more effective treatments. One cellular pathway implicated in lung cancer development and progression is that of the mammalian target of rapamycin. Studies involving human tissues have linked lung cancer with abnormalities in this pathway. Furthermore, studies in vitro and in vivo using animal models of lung cancer reveal that targeting this pathway might represent an effective means of treating this disease. As a result, there is significant effort invested in the development of drugs targeting mammalian target of rapamycin and related pathways in the clinical setting.
authors.affiliation: Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky.
authors.forename: Glenn W
authors.initials: GW
authors.lastname: Vicary
authors.affiliation: Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky; Division of Pulmonary, Critical Care, and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky; Lousiville Veterans Affairs Medical Center, Louisville, Kentucky. Electronic address: j.roman@louisville.edu.
authors.forename: Jesse
authors.initials: J
authors.lastname: Roman
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D058570:TOR Serine-Threonine Kinases
keywords: Lung cancer; Oncogenesis; Rapamycin; Signaling pathways; mTOR